Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).
Lead Product(s): PT00114
Therapeutic Area: Psychiatry/Psychology Product Name: PT00114
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 08, 2020